Influence of oral propranolol on growth and development of children with infantile hemangiomas

Abstract

Abstract: PURPOSE: To investigate the effect of oral propranolol on growth and development of children with infantile hemangioma(IH). METHODS: Children with IHs during Jan. 2010 and Aug. 2014 treated with surgery or oral propranolol in Qilu Hospital were recruited. The children were divided into surgery group and propranolol group. Phone calls and letters were used for investigation in December 2014. Ten indicators including weight, height (length), sitting height, head circumstance, chest circumstance, upper limber circumstance, body weight index (BMI), weight/height (length), chest/height and sitting height/height were selected to evaluate their growth and development levels. The data were analyzed based on Chinese Growth Reference Standards under 7 and WHO Child Growth Standards, and tested by age, sex and place of residence as covariates, covariance analysis. RESULTS: One hundred and eighteen cases (92 for propranolol and 26 for surgery) were included. Covariance analysis indicated significant differences of height and chest circumstance among 10 indicators between surgery and propranolol groups(P=0.038<0.05, P=0.041<0.05), and the height and chest of the propranolol were lower than those of surgery (11.11 cm and 3.25 cm) the average differences were 11.11 cm and 3.25 cm. CONCLUSIONS: Long-term oral propranolol may lead to hypoevolutism of height and chest circumference in children with IH.

Key words: Propranolol, Hemangiomas, Physical development

CLC Number:

R739.8

DONG Jian-yong, LI Kai, YUE Lin-lin, LI Rong-hui, HUANG Ying-ying, LIU Shao-hua. Influence of oral propranolol on growth and development of children with infantile hemangiomas[J]. China Journal of Oral and Maxillofacial Surgery, 2016, 14(6): 510-513.

References

[1] Goelz R, Poets CF. Incidence and treatment of infantile haemangioma in preterm infants [J]. Arch Dis Child-Fetal Neonatal Ed, 2015, 100(1): F85-91.
[2] Frieden IJ, Haggstrom AN, Drolet BA, et al. Infantile hemangiomas: current knowledge, future directions. Proceedings of a research workshop on infantile hemangiomas, April 7-9, 2005, Bethesda, Maryland, USA [J]. Pediatr Dermatol, 2005, 22(5): 383-406.
[3] Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy [J]. N Engl J Med, 2008, 358(24): 2649-2651.
[4] 郑家伟, 张凌, 陈正岗. 普萘洛尔治疗婴幼儿血管瘤专家共识 [J]. 中国口腔颌面外科杂志, 2013, 11(2): 161-164.
[5] Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference [J]. Pediatrics, 2013, 131(1): 128-140.
[6] Cissoko H, Jonville-Béra AP, Swortfiguer D, et al. Neonatal outcome after exposure to beta adrenergic blockers late in pregnancy [J]. Arch Pediatrie, 2005, 12(5): 543-547.
[7] Achauer BM, Chang CJ, Vander Kam VM. Management of hemangioma of infancy: review of 245 patients [J]. Plast Reconstr Surg, 1997, 99(5): 1301-1308.
[8] 王卫平. 儿科学[M]. 第8版. 北京: 人民卫生出版社, 2013: 8-15.
[9] World Health Organization. The WHO child growth evaluation software [DB/OL]. (2015-1-7)[2016-01-26]. http://www.who.int/childgrowth/software/en/.
[10] 中华人民共和国国家卫生和计划生育委员会. 卫生部妇社司关于印发《中国7岁以下儿童生长发育参照标准》的通知 [Z].
[11] 中华人民共和国国家卫生和计划生育委员会. 中国7岁以下儿童生长参照标准[EB/OL]. (2015-01-27)[2016-01-26]. http://www.nhfpc.gov.cn/fys/s3585/200906/a81e441c2f754cd2a1e2527b43eb376e.shtml.
[12] World Health Organization. The WHO child growth standards[DB/OL]. (2015-01-07)[2016-01-26]. http://www.who.int/childgrowth/standards/en/.
[13] 九市儿童体格发育调查协作组, 首都儿科研究所. 2005年中国九市七岁以下儿童体格发育调查[J]. 中华儿科杂志, 2007, 45(8): 609-614.
[14] Stiles J, Amaya C, Pham R, et al. Propranolol treatment of infantile hemangioma endothelial cells: A molecular analysis [J]. Exp Ther Med, 2012, 4(4): 594-604.
[15] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. β肾上腺素能受体阻滞剂在心血管疾病应用专家共识[J]. 中华心血管病杂志, 2009, 37(3): 195-209.